This should help explain drop yesterday....

Lots of shorts going to feel a real burn when the Walmart and Target deals are signed and the patent portfolio added.

Love when shorts get burned, this can easily be back to .05 and .06 today where it should be.

Buy and Burn em while its still cheap

Enjoy Longs!

http://otcshortreport.com/index.php?index=pmbs&action=view

Lots of Shorts going to get burned with this stock

What a tremendous buying opportunity down here.

There is easily a squeeze up to .10, .15 in our future

Check out the link, and grab as many shares as you can!!

http://otcshortreport.com/index.php?index=pmbs&action=view

Alright, add your 40K my friend....

I already have 300K and am holding for the boom back to $1.00 like we saw late 2012!!

This thing is PRIMED to explode as I shown in my communications with management and the IR

GLTA!

Directly from TRLI's investment firm

-----Original Message-----
From: Zachary R. Logan <pacificequityusa@gmail.com>
To: thesuby2 <xxxx>
Sent: Wed, May 22, 2013 8:00 pm
Subject: Mr. Massaro


Mr. Massaro,



Thank you for your patience in regards to a response to your thoughtful questions regarding the investment opportunity in Truli Media Group Inc. Here are brief answers:




Truli Media Group Inc. just switched Transfer Agents from Computershare Trust to V-Stock Transfer, all of the company information has been updated recently and Truli Media is compliant with their Transfer Agent responsibilities.




Our firm, Pacific Equity has completed due diligence on Truli Media Group Inc. and are in the process of "rolling out" our campaign to present TRLI as a sound investment for our accredited community.




I personally believe that with such a low float and being a pure-play in the Christian Media space the company is currently significantly undervalued. Our firm participates in active speculation so predict exactly where the PPS ends up is hared to predict. With having said that, we are looking forward to putting the company in front of the active retail community and seeing fundamental developments from the company which could validate a move on the open market.

I hope this reply can be helpful in your assessment of Truli Media Group Inc. Have a terrific day and do not hesitate to contact myself or anyone with the company directly. Thank you once again for your patience.


ZL









--



Zachary R. Logan

President

















PACIFIC EQUITY ALLIANCE LLC

www.pacificequityusa.com

858.886.7237

858.886.7238






Disclaimer: Pacific Equity Alliance, LLC. is an Independent Investor Relations firm that provides information on selected publicly traded companies. Pacific Equity Alliance, LLC. is not a United States Securities Dealer or Broker or United States registered Investment Adviser. This email letter and any and all attachments and related documents are never considered to be asolicitation for any purpose in any form or content. Pacific Equity Alliance, LLC.'s Affiliates, Officers, Directors and Employees will buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value. Please do your own due diligence before investing in any of the stocks mentioned above. Upon receipt of these documents you, as the Recipient, hereby acknowledge this Warning and Disclaimer. These Confidential communications are protected under Gramm-Leach-Bailey Act 15 USC, Sub chapter 1, sections 6801-6809 and other laws addressing the disclosure of Non-Public Personal Information.


Confidential: The contents of this message, together with any attachments, are intended only for the use of the individual or entity to which they are addressed and may contain information that s legally privileged, confidential and exempt from disclosure. This communication is for information purposes only and should not be regarded as an offer to sell or as a solicitation of an offer to buy any financial product, an official confirmation of any transaction, or as an official statement of the Sender or its Principals. Email transmission cannot be guaranteed to be secure or error-free. The Sender, its affiliates and or assigns does not represent that this information is complete or accurate and it should not be relied upon as such. All information is subject to change without notice. If you are not the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this message, or any attachment, is strictly prohibited. If you have received this message in error, please notify the original sender by return E-mail and delete this message, along with any attachments, from your computer

1st Quarter PROFIT!

Only a sign of things to come my friends

Added 20K more today.....

Raising of the outstanding will NOT happen like you are expecting

Read the filing, this company is committed to keeping the O/S low and shareholder value as high as possible. They will most likely issue a divy for existing shareholders. They have so many great things happening, its only a matter of time before we are back in the teams and above. And even if the O/S was 165 mil like you say, would a 20-30 million dollar market cap be so bad? I don't think so and that would be 400% from here. Lets not be short sighted, too many profits and huge potential from here!

GLTA

Also, INSIDER BUYING!!!!

http://finance.yahoo.com/q/it?s=PMBS+Insider+Transactions

Don't think he would be buying 6 million shares (20% of the float) if they didn't know what they were doing.

Added 300K today

Definitely worth it at these levels, such low float (yes I know about the filing, but that does not mean it will happen nor if did happen, they would dilute)

.20 target already on the stock
revenue generating
and expanding into the WORLDS biggest retailers

Yes, I will keep adding at these levels, you would be a fool not too!

Also, HEAVY Insider Buying

Keep in mind Jay Solomon bought 18 Million shares at .07 back in February of this year at .07, and has 53 million of the float, don't think he would be in that much to let this sink.

http://finance.yahoo.com/q/it?s=TRLI+Insider+Transactions

This is an unbelievably strong buy from here....

GOOD INFO, Behind the scenes happenings, must read

I have been in contact with Chuck Arnold from Truli and he guided me to their new investment banker Zachery Logan. Pacfic Equity is going to be representing them, loves what they see and will be bringing in their own investors in the stock.

Needless to say, this is a TREMENDOUS opportunity to buy low here, because when they start buying, and with such a small float, there wont be much left and the price will sky rocket.

I have 250K shares and we are going to have a great summer with TRLI....

GLTA, but get in Now....

-----Original Message-----
From: Pacific Equity <info@pacificequityusa.com>
To: xxxx <xxxx@aol.com>
Sent: Tue, May 7, 2013 1:32 pm
Subject: Re: Mr. xxxx


Mr. xxxx,



Thank you for your intelligent and prompt response in regards to Truli Media Group Inc.


Our firm, Pacific Equity will be representing TRLI on the market shortly. We are currently waiting on information from the company's transfer agent prior to commencing activity. In regards to rapid growth, we believe in the company and we have a strong following of investors which will be introduced to TRLI in the Summer and Spring months of 2013. I am going to get you a retail piece which includes revenue projections. You should know you will be the first investor to see our company's retail piece on the company. The company is well versed in advertising & social media which is another form of exposure which should effect the company in a positive way moving forward. Our firm is very optimistic about the potential upside from here regarding TRLI. We know it is a sound investment for our firm as well as the investor who invest with our firm. I hope this information has been helpful. Have a terrific day.




Respectfully,




ZL



On Mon, May 6, 2013 at 1:10 PM, <thesuby2@aol.com> wrote:


Hello Zach

Thank you for the quick response. Couple questions for you



1. Are You currently representing the company today in IR outreach as of today, if not when do you start?

2. When you say rapid growth for TRLI for the summer and fall, what do you mean by that (Have heard stories like this millions of times, please provide some specifics)

3. Can we put out some revenue projections since TRLI is now making revenue.

4. What else is being done to promote this company to the public?



Thanks very much for your assistance





-----Original Message-----
From: Zachary R. Logan <pacificequityusa@gmail.com>
To: xxxx <xxxx@aol.com>
Sent: Mon, May 6, 2013 12:50 pm
Subject: Mr. xxxx


Mr. XXXX,



I am aware that you are a long time shareholder of Truli Media Group Inc. : TRLI. as indicated from Mr. Charles Arnold. I would like you to know that our firm is currently in talks with management and will be actively representing the company on the open market. We are honored & thrilled to be a part of this faith based company. Our team is currently conducting due diligence on TRLI & we are extremely optimistic moving forward for the opportunity for our community of investors to take part in TRLI. We anticipate rapid growth this summer & fall for Truli. I welcome the opportunity to speak with you directly in depth regarding TRLI & hope you are having a good start to your Monday.


Respectfully,



--



Zachary R. Logan

President

















PACIFIC EQUITY ALLIANCE LLC

www.pacificequityusa.com

858.886.7237

858.886.7238






Disclaimer: Pacific Equity Alliance, LLC. is an Independent Investor Relations firm that provides information on selected publicly traded companies. Pacific Equity Alliance, LLC. is not a United States Securities Dealer or Broker or United States registered Investment Adviser. This email letter and any and all attachments and related documents are never considered to be asolicitation for any purpose in any form or content. Pacific Equity Alliance, LLC.'s Affiliates, Officers, Directors and Employees will buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value. Please do your own due diligence before investing in any of the stocks mentioned above. Upon receipt of these documents you, as the Recipient, hereby acknowledge this Warning and Disclaimer. These Confidential communications are protected under Gramm-Leach-Bailey Act 15 USC, Sub chapter 1, sections 6801-6809 and other laws addressing the disclosure of Non-Public Personal Information.


Confidential: The contents of this message, together with any attachments, are intended only for the use of the individual or entity to which they are addressed and may contain information that s legally privileged, confidential and exempt from disclosure. This communication is for information purposes only and should not be regarded as an offer to sell or as a solicitation of an offer to buy any financial product, an official confirmation of any transaction, or as an official statement of the Sender or its Principals. Email transmission cannot be guaranteed to be secure or error-free. The Sender, its affiliates and or assigns does not represent that this information is complete or accurate and it should not be relied upon as such. All information is subject to change without notice. If you are not the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this message, or any attachment, is strictly prohibited. If you have received this message in error, please notify the original sender by return E-mail and delete this message, along with any attachments, from your computer





--


Lauren Timmons

Executive Assistant
















PACIFIC EQUITY ALLIANCE LLC

www.pacificequityusa.com

858.886.7237

858.886.7238











Disclaimer: Pacific Equity Alliance, LLC. is an Independent Investor Relations firm that provides information on selected publicly traded companies. Pacific Equity Alliance, LLC. is not a United States Securities Dealer or Broker or United States registered Investment Adviser. This email letter and any and all attachments and related documents are never considered to be asolicitation for any purpose in any form or content. Pacific Equity Alliance, LLC.'s Affiliates, Officers, Directors and Employees will buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value. Please do your own due diligence before investing in any of the stocks mentioned above. Upon receipt of these documents you, as the Recipient, hereby acknowledge this Warning and Disclaimer. These Confidential communications are protected under Gramm-Leach-Bailey Act 15 USC, Sub chapter 1, sections 6801-6809 and other laws addressing the disclosure of Non-Public Personal Information.


Confidential: The contents of this message, together with any attachments, are intended only for the use of the individual or entity to which they are addressed and may contain information that s legally privileged, confidential and exempt from disclosure. This communication is for information purposes only and should not be regarded as an offer to sell or as a solicitation of an offer to buy any financial product, an official confirmation of any transaction, or as an official statement of the Sender or its Principals. Email transmission cannot be guaranteed to be secure or error-free. The Sender, its affiliates and or assigns does not represent that this information is complete or accurate and it should not be relied upon as such. All information is subject to change without notice. If you are not the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this message, or any attachment, is strictly prohibited. If you have received this message in error, please notify the original sender by return E-mail and delete this message, along with any attachments, from your computer

HUGE NEWS OUT --> XXII.....Must Must Read!

Real Revenues,
Talks and tests with Pfizer, More effective than Chantix and thats medically proven!

22nd Century Group, Inc. (OTCBB: XXII) today announced that its subsidiary Goodrich Tobacco Company has entered into an exclusive distribution agreement with Wilshire Marketing BV for the DUTCH MAGIC™ brand in The Netherlands, Belgium and Luxemburg, known as Benelux.

DUTCH MAGIC consists of two cigarette brand styles and two roll-your-own brand styles. Unlike “light” and “ultra light” cigarette brands, which essentially have the same nicotine content as full flavor brands, DUTCH MAGIC cigarettes have a nicotine content that is significantly reduced. The very low nicotine Dutch Magic brand style contains approximately 95% less nicotine than typical “ultra light” and “light” cigarettes.

The Netherlands, Belgium and Luxemburg are the first European countries in which very low nicotine tobacco products will be available to consumers. Goodrich Tobacco Company will ship Wilshire’s initial order of 450,000 packs of DUTCH MAGIC in July 2013. The exclusive distribution agreement requires minimum annual purchases by Wilshire Marketing BV that peak at $3,000,000 in calendar year 2015. Wilshire Marketing BV is investing substantial marketing funds to launch DUTCH MAGIC in Benelux.

Henry Sicignano III, president of Goodrich Tobacco, stated, “We are very pleased to be working with Wilshire and are excited about the distribution of our proprietary DUTCH MAGIC cigarettes in Europe.” 22nd Century expects ongoing discussions with various parties in the tobacco and pharmaceutical industries to result in additional licensing agreements for its proprietary technology and products over the next few months.

HUGE NEWS OUT --> XXII.....Must Must Read!

Real Revenues,
Talks and tests with Pfizer, More effective than Chantix and thats medically proven!

22nd Century Group, Inc. (OTCBB: XXII) today announced that its subsidiary Goodrich Tobacco Company has entered into an exclusive distribution agreement with Wilshire Marketing BV for the DUTCH MAGIC™ brand in The Netherlands, Belgium and Luxemburg, known as Benelux.

DUTCH MAGIC consists of two cigarette brand styles and two roll-your-own brand styles. Unlike “light” and “ultra light” cigarette brands, which essentially have the same nicotine content as full flavor brands, DUTCH MAGIC cigarettes have a nicotine content that is significantly reduced. The very low nicotine Dutch Magic brand style contains approximately 95% less nicotine than typical “ultra light” and “light” cigarettes.

The Netherlands, Belgium and Luxemburg are the first European countries in which very low nicotine tobacco products will be available to consumers. Goodrich Tobacco Company will ship Wilshire’s initial order of 450,000 packs of DUTCH MAGIC in July 2013. The exclusive distribution agreement requires minimum annual purchases by Wilshire Marketing BV that peak at $3,000,000 in calendar year 2015. Wilshire Marketing BV is investing substantial marketing funds to launch DUTCH MAGIC in Benelux.

Henry Sicignano III, president of Goodrich Tobacco, stated, “We are very pleased to be working with Wilshire and are excited about the distribution of our proprietary DUTCH MAGIC cigarettes in Europe.” 22nd Century expects ongoing discussions with various parties in the tobacco and pharmaceutical industries to result in additional licensing agreements for its proprietary technology and products over the next few months.

was this recent? good thing/bad thing?

Really more tremendous news, only a matter of time before we explode up, get taken over, merge etc.

Think its time to add a little more here.

XXII - HUGE NEWS, must read!!!

Next Step is FDA approval and/or merger with Pfizer...

Read, Research and make huge profit from here...

22nd Century Group, Inc. (OTCBB: XXII), a company that has developed groundbreaking technology for tobacco harm reduction products, today announced that the United States Patent and Trademark Office (US PTO) has issued Patent No. 8,410,341 for the N-methylputrescine oxidase (MPO) gene technology. MPO is essential for production of nicotine in the tobacco plant. As previously announced, the US PTO issued a Notice of Allowance on December 24, 2012 for this technology; however, yesterday’s issuance marks the official grant of the patent.
The allowed claims of Patent No. 8,410,341, entitled, NUCLEIC ACID ENCODING N-METHYLPUTRESCINE OXIDASE AND USES THEREOF, cover nucleic acids encoding MPO, methods for producing tobacco plants with either reduced or increased nicotine levels and tobacco plants produced by the foregoing. The US PTO granted Patent No. 8,410,341 on April 2, 2013 to the National Research Council Canada (NRC). 22nd Century is NRC’s exclusive worldwide licensee of MPO and other technologies.
Patent No. 8,410,341 is the first MPO gene patent issued anywhere in the world. Including the patent term adjustment, this U.S. patent will expire in December 2027. Patent Application PCT/IB2007/003550 is the related international application to U.S. Patent No. 8,410,341. Additional MPO patent applications are pending in the U.S., Canada and China.
The MPO gene encodes a protein involved in a key step of nicotine biosynthesis. Scientists have attempted to clone the MPO gene for decades. MPO expression can be either down-regulated or up-regulated to produce tobacco plant varieties and tobacco products with a wide range of nicotine levels (from very low to high), or altered ratios of nicotine and other nicotinic alkaloids such as anatabine and nornicotine. Dr. Jonathon Page and Enwu Liu of the NRC Plant Biotechnology Institute are the inventors of the MPO technology. 22nd Century funded subject patent and research and development expenses at NRC from 2006 to 2008.
The MPO gene technology is one of several 22nd Century patent families representing the company’s second-generation gene technology for modifying the content of nicotine and other nicotinic alkaloids in the tobacco plant. 22nd Century’s vice president of research and development, Dr. Michael Moynihan stated, “We are very pleased that the US PTO has granted the MPO patent. Our second-generation technology has significant advantages over our first generation technology.”
22nd Century’s patent portfolio consists of 15 issued U.S. patents and 9 pending U.S. patent applications. Globally, 22nd Century owns or is the exclusive licensee of 109 issued patents in 78 countries plus an additional 39 pending patent applications – mainly related to all of the key nicotine biosynthesis genes and transcription factors and tobacco harm reduction products produced therefrom.

XXII - HUGE NEWS, must read!!!

Next Step is FDA approval and/or merger with Pfizer...

Read, Research and make huge profit from here...

22nd Century Group, Inc. (OTCBB: XXII), a company that has developed groundbreaking technology for tobacco harm reduction products, today announced that the United States Patent and Trademark Office (US PTO) has issued Patent No. 8,410,341 for the N-methylputrescine oxidase (MPO) gene technology. MPO is essential for production of nicotine in the tobacco plant. As previously announced, the US PTO issued a Notice of Allowance on December 24, 2012 for this technology; however, yesterday’s issuance marks the official grant of the patent.
The allowed claims of Patent No. 8,410,341, entitled, NUCLEIC ACID ENCODING N-METHYLPUTRESCINE OXIDASE AND USES THEREOF, cover nucleic acids encoding MPO, methods for producing tobacco plants with either reduced or increased nicotine levels and tobacco plants produced by the foregoing. The US PTO granted Patent No. 8,410,341 on April 2, 2013 to the National Research Council Canada (NRC). 22nd Century is NRC’s exclusive worldwide licensee of MPO and other technologies.
Patent No. 8,410,341 is the first MPO gene patent issued anywhere in the world. Including the patent term adjustment, this U.S. patent will expire in December 2027. Patent Application PCT/IB2007/003550 is the related international application to U.S. Patent No. 8,410,341. Additional MPO patent applications are pending in the U.S., Canada and China.
The MPO gene encodes a protein involved in a key step of nicotine biosynthesis. Scientists have attempted to clone the MPO gene for decades. MPO expression can be either down-regulated or up-regulated to produce tobacco plant varieties and tobacco products with a wide range of nicotine levels (from very low to high), or altered ratios of nicotine and other nicotinic alkaloids such as anatabine and nornicotine. Dr. Jonathon Page and Enwu Liu of the NRC Plant Biotechnology Institute are the inventors of the MPO technology. 22nd Century funded subject patent and research and development expenses at NRC from 2006 to 2008.
The MPO gene technology is one of several 22nd Century patent families representing the company’s second-generation gene technology for modifying the content of nicotine and other nicotinic alkaloids in the tobacco plant. 22nd Century’s vice president of research and development, Dr. Michael Moynihan stated, “We are very pleased that the US PTO has granted the MPO patent. Our second-generation technology has significant advantages over our first generation technology.”
22nd Century’s patent portfolio consists of 15 issued U.S. patents and 9 pending U.S. patent applications. Globally, 22nd Century owns or is the exclusive licensee of 109 issued patents in 78 countries plus an additional 39 pending patent applications – mainly related to all of the key nicotine biosynthesis genes and transcription factors and tobacco harm reduction products produced therefrom.

Thats a really awesome article and a good sign of things to come. When the CEO invests that much of his own money and is generating revenue with such low cost overhead....this thing could be back to a $1 or higher in no time with such a low float!

A Companion play for AFFY.....

ARYC has and still is aggressively in talks to be a companion diagnostic savior for AFFY. Here's emails with the CEO below discussing and the news article to shed more lite

ARYC .18 with revenue, AFFY 1.35 without....think a big partnership is on the horizon!

On 03/19/13, Mark Schena<mark@arrayit.com> wrote:

Hi Michael, The Affymax announcement probably improves our chances for a deal because it creates urgency for a companion diagnostic. PRs will be forthcoming shortly. Thanks, mark

Sent from my iPhone


Mark Schena, Ph.D.
President
Arrayit Corporation (ARYC)
524 East Weddell Drive
Sunnyvale, CA 94089
USA


Phone 408-744-1331
Fax 408-744-1711
Mobile 650-248-8710
Email mark@arrayit.com
Web http://arrayit.com


Notice of content filtering and monitoring: Arrayit Corporation and its subsidiaries and business units (collectively, “Arrayit” and “the Company”) reserve the right to monitor, filter and archive all e-mail communications sent and/or received by its employees. Arrayit is not responsible for any typographical error and any pricing or offers contained in this e-mail are subject to change without notice. Notice of proprietary and/or material information: This e-mail and any of its attachments may contain proprietary and/or material information that may be deemed privileged, confidential or subject to copyright belonging to Arrayit. This e-mail is intended solely for the use of the individual or entity to which it is addressed. If you are not the intended recipient of this e-mail, you are hereby notified that any dissemination, distribution, copying, or action taken in relation to the contents of and attachments to this e-mail is strictly prohibited and may be unlawful. If you have received this e-mail in error, please notify the Sender immediately by telephone at 408-744-1331, and permanently delete the original and any copy or printout. Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this email may include forward-looking statements that involve certain risks and uncertainties detailed in the Company’s filings with the Securities and Exchange Commission. For information provided by Arrayit with respect to its business and business prospects, as well as the risks associated with an investment in our Company’s publicly traded securities, please see the Company’s reports filed with the U.S. Securities and Exchange Commission, copies of which are available at www.sec.gov and also on the Company website, found at www.arrayit.com.

On Mar 19, 2013, at 5:29 AM, xxxx@verizon.net wrote:


Hello All
I am assuming with Affymax's announcement yesterday, does this put them out of the picture?

Also, can we get any PR updates on events happening, its been pretty quiet for a long time now?

Thanks again for your responses, really looking forward to seeing results after all these years now.




On 03/14/13, arrayit@arrayit.com wrote:

Dear Michael, Enclosed is Dr. Schena's response from yesterday. Thanks
very much for your support!


Arrayit Corp


From: mark@arrayit.com
Subject: Re: Urgent Please Respond
Date: March 13, 2013 11:34:10 AM PDT
To: xxxx@verizon.net
Cc: sscott@issuerscap.com

Hi Michael, Very nice to hear from you! Are you the PT in Buffalo or
another shareholder? Either way, we appreciate your support. Here's the
info. Thanks, mark



On Mar 13, 2013, at 9:45 AM, xxxx@verizon.net wrote:

Hello Arrayit Corp
I have been a long time very frustrated investor (own 151,000 shares) of
your company and I am looking for some answers to my questions below.

Rene and I own 22,000,000 shares of ARYC, so believe me when I tell you we
are on the same team!



Please be as specific as you can.

1. When is the spinoff going to be approved and happen so that we receive
our shares

Our new CEO Steve Scott of Avant Diagnostics plans to distribute the
dividend as soon as possible after the initial $1M capital raise. Steve
can provide an update.



2. What is going on with the financing for a possible FDA approval in 2Q

Steve can provide an update on the financing and FDA submission.



3. Is there a partnership on the horizon with AFFY - Affymax?

We have reached out to Affymax (AFFY) with a very exciting proposal and we
are awaiting a response from the company's Chief Medical Officer.




I anxiously look forward to your detailed response to these questions above

Thanks

PR Release:
http://finance.yahoo.com/news/arrayits-potential-blockbuster-companion-diagnostic-140000367.html
The pharmaceutical industry can be a volatile place to invest, with share prices relying on successful clinical trials and ongoing regulatory compliance. In many cases, companies could reduce these risks by properly vetting clinical trial participants and patients in order to ensure that they are treating the right patients. The personalized medicine movement could help in this regard with the growing popularity of so-called companion diagnostics.

Demonstrating a Market Need

On February 25, 2013, Affymax Inc. (NASDAQ:AFFY) shares lost approximately 85% of their value, falling from $16.52 to $2.42 per share in a single day, wiping away more than $500 million in market capitalization in the process. The move came after the company voluntarily pulled its anemia drug, Omontys, used to treat kidney dialysis, following news that 50 adverse reactions were discovered in 25,000 patients treated, including at least five deaths.

The problem observed in these 50 patients was hypersensitivity – a sometimes-fatal condition that arises when the body’s immune system reacts to certain drugs or other intrusions, like bee stings, according to the Wall Street Journal. Since a relatively small patient population was tested in clinical trials, these side effects went unnoticed until the drug was exposed to a larger patient population, thereby leading to significant and unexpected shareholder losses.

Ways to Improve Outcomes

Companion diagnostic tests are molecular assays that measure levels of proteins, genes or specific mutations in order to provide the right treatment to the right patient. In Affymax’s case, companion diagnostics could be used to ensure that the patient being treated was not hypersensitive to Omontys. This would thereby avoid adverse events, while providing the convenience-related benefits compared to Amgen Inc.’s (AMGN) Epogen.

Arrayit Corporation (ARYC), already a leader in the microarray industry providing specialized solutions, has also branched out into the molecular diagnostics business to provide these tools. With the industry’s only printing technology that can deposit any kind of molecule and host up to 100,000 patient samples on a single microarray, the company is uniquely positioned compared to industry competitors like Affymetrix Inc. (NASDAQ:AFFX).

Creating Value for All Parties

In the earlier example of AffyMax’s fall, Arrayit’s technologies could be used in order to expedite Omontys’ return to market. The company’s blood cards could be used to sample blood from 25,000 patients at the point-of-care, which could then be input into its VIP technology for low-cost targeted genotyping. Meanwhile, its H25K could be used to perform whole genome expression profiling, while peptide microarrays could be used to test for patient antibodies.

Essentially, Arrayit’s role as a companion diagnostic could help companies like AffyMax get products like Omontys back on the market more quickly. And the same technology could be used to ensure patients are properly enrolled in clinical trials, confirm the right patients being treated with approved drugs, and assist other pharmaceutical companies in regaining regulatory compliance after a drug has been found unsafe in certain populations.

Potential Investment Opportunity

Arrayit Corporation (ARYC) represents an attractive investment opportunity given its unique technology platform and potential in the pharmaceutical industry. Moreover, its patent protected technology remains the only platform amenable to cost-effective screening of the human population, with the ability to run thousands of patient samples at a time with 100% accuracy provided that the tests are performed correctly.

Easy way to play AFFY with much less risk Must Read

ARYC has and still is aggressively in talks to be a companion diagnostic savior for AFFY. Here's emails with the CEO below discussing and the news article to shed more lite

ARYC .18 with revenue, AFFY 1.35 without....think a big partnership is on the horizon!

On 03/19/13, Mark Schena<mark@arrayit.com> wrote:

Hi Michael, The Affymax announcement probably improves our chances for a deal because it creates urgency for a companion diagnostic. PRs will be forthcoming shortly. Thanks, mark

Sent from my iPhone


Mark Schena, Ph.D.
President
Arrayit Corporation (ARYC)
524 East Weddell Drive
Sunnyvale, CA 94089
USA


Phone 408-744-1331
Fax 408-744-1711
Mobile 650-248-8710
Email mark@arrayit.com
Web http://arrayit.com


Notice of content filtering and monitoring: Arrayit Corporation and its subsidiaries and business units (collectively, “Arrayit” and “the Company”) reserve the right to monitor, filter and archive all e-mail communications sent and/or received by its employees. Arrayit is not responsible for any typographical error and any pricing or offers contained in this e-mail are subject to change without notice. Notice of proprietary and/or material information: This e-mail and any of its attachments may contain proprietary and/or material information that may be deemed privileged, confidential or subject to copyright belonging to Arrayit. This e-mail is intended solely for the use of the individual or entity to which it is addressed. If you are not the intended recipient of this e-mail, you are hereby notified that any dissemination, distribution, copying, or action taken in relation to the contents of and attachments to this e-mail is strictly prohibited and may be unlawful. If you have received this e-mail in error, please notify the Sender immediately by telephone at 408-744-1331, and permanently delete the original and any copy or printout. Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this email may include forward-looking statements that involve certain risks and uncertainties detailed in the Company’s filings with the Securities and Exchange Commission. For information provided by Arrayit with respect to its business and business prospects, as well as the risks associated with an investment in our Company’s publicly traded securities, please see the Company’s reports filed with the U.S. Securities and Exchange Commission, copies of which are available at www.sec.gov and also on the Company website, found at www.arrayit.com.

On Mar 19, 2013, at 5:29 AM, xxxx@verizon.net wrote:


Hello All
I am assuming with Affymax's announcement yesterday, does this put them out of the picture?

Also, can we get any PR updates on events happening, its been pretty quiet for a long time now?

Thanks again for your responses, really looking forward to seeing results after all these years now.




On 03/14/13, arrayit@arrayit.com wrote:

Dear Michael, Enclosed is Dr. Schena's response from yesterday. Thanks
very much for your support!


Arrayit Corp


From: mark@arrayit.com
Subject: Re: Urgent Please Respond
Date: March 13, 2013 11:34:10 AM PDT
To: xxxx@verizon.net
Cc: sscott@issuerscap.com

Hi Michael, Very nice to hear from you! Are you the PT in Buffalo or
another shareholder? Either way, we appreciate your support. Here's the
info. Thanks, mark



On Mar 13, 2013, at 9:45 AM, xxxx@verizon.net wrote:

Hello Arrayit Corp
I have been a long time very frustrated investor (own 151,000 shares) of
your company and I am looking for some answers to my questions below.

Rene and I own 22,000,000 shares of ARYC, so believe me when I tell you we
are on the same team!



Please be as specific as you can.

1. When is the spinoff going to be approved and happen so that we receive
our shares

Our new CEO Steve Scott of Avant Diagnostics plans to distribute the
dividend as soon as possible after the initial $1M capital raise. Steve
can provide an update.



2. What is going on with the financing for a possible FDA approval in 2Q

Steve can provide an update on the financing and FDA submission.



3. Is there a partnership on the horizon with AFFY - Affymax?

We have reached out to Affymax (AFFY) with a very exciting proposal and we
are awaiting a response from the company's Chief Medical Officer.




I anxiously look forward to your detailed response to these questions above

Thanks

PR Release:
http://finance.yahoo.com/news/arrayits-potential-blockbuster-companion-diagnostic-140000367.html
The pharmaceutical industry can be a volatile place to invest, with share prices relying on successful clinical trials and ongoing regulatory compliance. In many cases, companies could reduce these risks by properly vetting clinical trial participants and patients in order to ensure that they are treating the right patients. The personalized medicine movement could help in this regard with the growing popularity of so-called companion diagnostics.

Demonstrating a Market Need

On February 25, 2013, Affymax Inc. (NASDAQ:AFFY) shares lost approximately 85% of their value, falling from $16.52 to $2.42 per share in a single day, wiping away more than $500 million in market capitalization in the process. The move came after the company voluntarily pulled its anemia drug, Omontys, used to treat kidney dialysis, following news that 50 adverse reactions were discovered in 25,000 patients treated, including at least five deaths.

The problem observed in these 50 patients was hypersensitivity – a sometimes-fatal condition that arises when the body’s immune system reacts to certain drugs or other intrusions, like bee stings, according to the Wall Street Journal. Since a relatively small patient population was tested in clinical trials, these side effects went unnoticed until the drug was exposed to a larger patient population, thereby leading to significant and unexpected shareholder losses.

Ways to Improve Outcomes

Companion diagnostic tests are molecular assays that measure levels of proteins, genes or specific mutations in order to provide the right treatment to the right patient. In Affymax’s case, companion diagnostics could be used to ensure that the patient being treated was not hypersensitive to Omontys. This would thereby avoid adverse events, while providing the convenience-related benefits compared to Amgen Inc.’s (AMGN) Epogen.

Arrayit Corporation (ARYC), already a leader in the microarray industry providing specialized solutions, has also branched out into the molecular diagnostics business to provide these tools. With the industry’s only printing technology that can deposit any kind of molecule and host up to 100,000 patient samples on a single microarray, the company is uniquely positioned compared to industry competitors like Affymetrix Inc. (NASDAQ:AFFX).

Creating Value for All Parties

In the earlier example of AffyMax’s fall, Arrayit’s technologies could be used in order to expedite Omontys’ return to market. The company’s blood cards could be used to sample blood from 25,000 patients at the point-of-care, which could then be input into its VIP technology for low-cost targeted genotyping. Meanwhile, its H25K could be used to perform whole genome expression profiling, while peptide microarrays could be used to test for patient antibodies.

Essentially, Arrayit’s role as a companion diagnostic could help companies like AffyMax get products like Omontys back on the market more quickly. And the same technology could be used to ensure patients are properly enrolled in clinical trials, confirm the right patients being treated with approved drugs, and assist other pharmaceutical companies in regaining regulatory compliance after a drug has been found unsafe in certain populations.

Potential Investment Opportunity

Arrayit Corporation (ARYC) represents an attractive investment opportunity given its unique technology platform and potential in the pharmaceutical industry. Moreover, its patent protected technology remains the only platform amenable to cost-effective screening of the human population, with the ability to run thousands of patient samples at a time with 100% accuracy provided that the tests are performed correctly.

Easy way to play AFFY with much less risk Must Read

ARYC has and still is aggressively in talks to be a companion diagnostic savior for AFFY. Here's emails with the CEO below discussing and the news article to shed more lite

ARYC .18 with revenue, AFFY 1.35 without....think a big partnership is on the horizon!

On 03/19/13, Mark Schena<mark@arrayit.com> wrote:

Hi Michael, The Affymax announcement probably improves our chances for a deal because it creates urgency for a companion diagnostic. PRs will be forthcoming shortly. Thanks, mark

Sent from my iPhone


Mark Schena, Ph.D.
President
Arrayit Corporation (ARYC)
524 East Weddell Drive
Sunnyvale, CA 94089
USA


Phone 408-744-1331
Fax 408-744-1711
Mobile 650-248-8710
Email mark@arrayit.com
Web http://arrayit.com


Notice of content filtering and monitoring: Arrayit Corporation and its subsidiaries and business units (collectively, “Arrayit” and “the Company”) reserve the right to monitor, filter and archive all e-mail communications sent and/or received by its employees. Arrayit is not responsible for any typographical error and any pricing or offers contained in this e-mail are subject to change without notice. Notice of proprietary and/or material information: This e-mail and any of its attachments may contain proprietary and/or material information that may be deemed privileged, confidential or subject to copyright belonging to Arrayit. This e-mail is intended solely for the use of the individual or entity to which it is addressed. If you are not the intended recipient of this e-mail, you are hereby notified that any dissemination, distribution, copying, or action taken in relation to the contents of and attachments to this e-mail is strictly prohibited and may be unlawful. If you have received this e-mail in error, please notify the Sender immediately by telephone at 408-744-1331, and permanently delete the original and any copy or printout. Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this email may include forward-looking statements that involve certain risks and uncertainties detailed in the Company’s filings with the Securities and Exchange Commission. For information provided by Arrayit with respect to its business and business prospects, as well as the risks associated with an investment in our Company’s publicly traded securities, please see the Company’s reports filed with the U.S. Securities and Exchange Commission, copies of which are available at www.sec.gov and also on the Company website, found at www.arrayit.com.

On Mar 19, 2013, at 5:29 AM, xxxx@verizon.net wrote:


Hello All
I am assuming with Affymax's announcement yesterday, does this put them out of the picture?

Also, can we get any PR updates on events happening, its been pretty quiet for a long time now?

Thanks again for your responses, really looking forward to seeing results after all these years now.




On 03/14/13, arrayit@arrayit.com wrote:

Dear Michael, Enclosed is Dr. Schena's response from yesterday. Thanks
very much for your support!


Arrayit Corp


From: mark@arrayit.com
Subject: Re: Urgent Please Respond
Date: March 13, 2013 11:34:10 AM PDT
To: xxxx@verizon.net
Cc: sscott@issuerscap.com

Hi Michael, Very nice to hear from you! Are you the PT in Buffalo or
another shareholder? Either way, we appreciate your support. Here's the
info. Thanks, mark



On Mar 13, 2013, at 9:45 AM, xxxx@verizon.net wrote:

Hello Arrayit Corp
I have been a long time very frustrated investor (own 151,000 shares) of
your company and I am looking for some answers to my questions below.

Rene and I own 22,000,000 shares of ARYC, so believe me when I tell you we
are on the same team!



Please be as specific as you can.

1. When is the spinoff going to be approved and happen so that we receive
our shares

Our new CEO Steve Scott of Avant Diagnostics plans to distribute the
dividend as soon as possible after the initial $1M capital raise. Steve
can provide an update.



2. What is going on with the financing for a possible FDA approval in 2Q

Steve can provide an update on the financing and FDA submission.



3. Is there a partnership on the horizon with AFFY - Affymax?

We have reached out to Affymax (AFFY) with a very exciting proposal and we
are awaiting a response from the company's Chief Medical Officer.




I anxiously look forward to your detailed response to these questions above

Thanks

PR Release:
http://finance.yahoo.com/news/arrayits-potential-blockbuster-companion-diagnostic-140000367.html
The pharmaceutical industry can be a volatile place to invest, with share prices relying on successful clinical trials and ongoing regulatory compliance. In many cases, companies could reduce these risks by properly vetting clinical trial participants and patients in order to ensure that they are treating the right patients. The personalized medicine movement could help in this regard with the growing popularity of so-called companion diagnostics.

Demonstrating a Market Need

On February 25, 2013, Affymax Inc. (NASDAQ:AFFY) shares lost approximately 85% of their value, falling from $16.52 to $2.42 per share in a single day, wiping away more than $500 million in market capitalization in the process. The move came after the company voluntarily pulled its anemia drug, Omontys, used to treat kidney dialysis, following news that 50 adverse reactions were discovered in 25,000 patients treated, including at least five deaths.

The problem observed in these 50 patients was hypersensitivity – a sometimes-fatal condition that arises when the body’s immune system reacts to certain drugs or other intrusions, like bee stings, according to the Wall Street Journal. Since a relatively small patient population was tested in clinical trials, these side effects went unnoticed until the drug was exposed to a larger patient population, thereby leading to significant and unexpected shareholder losses.

Ways to Improve Outcomes

Companion diagnostic tests are molecular assays that measure levels of proteins, genes or specific mutations in order to provide the right treatment to the right patient. In Affymax’s case, companion diagnostics could be used to ensure that the patient being treated was not hypersensitive to Omontys. This would thereby avoid adverse events, while providing the convenience-related benefits compared to Amgen Inc.’s (AMGN) Epogen.

Arrayit Corporation (ARYC), already a leader in the microarray industry providing specialized solutions, has also branched out into the molecular diagnostics business to provide these tools. With the industry’s only printing technology that can deposit any kind of molecule and host up to 100,000 patient samples on a single microarray, the company is uniquely positioned compared to industry competitors like Affymetrix Inc. (NASDAQ:AFFX).

Creating Value for All Parties

In the earlier example of AffyMax’s fall, Arrayit’s technologies could be used in order to expedite Omontys’ return to market. The company’s blood cards could be used to sample blood from 25,000 patients at the point-of-care, which could then be input into its VIP technology for low-cost targeted genotyping. Meanwhile, its H25K could be used to perform whole genome expression profiling, while peptide microarrays could be used to test for patient antibodies.

Essentially, Arrayit’s role as a companion diagnostic could help companies like AffyMax get products like Omontys back on the market more quickly. And the same technology could be used to ensure patients are properly enrolled in clinical trials, confirm the right patients being treated with approved drugs, and assist other pharmaceutical companies in regaining regulatory compliance after a drug has been found unsafe in certain populations.

Potential Investment Opportunity

Arrayit Corporation (ARYC) represents an attractive investment opportunity given its unique technology platform and potential in the pharmaceutical industry. Moreover, its patent protected technology remains the only platform amenable to cost-effective screening of the human population, with the ability to run thousands of patient samples at a time with 100% accuracy provided that the tests are performed correctly.

Sometimes people do not realize nor know how to read a 10K.

Some people also dont realize how involved a small company named Pfizer is involved with everything and the possibilities of a buyout/merger/partnership.

Just sayin

But hey, thanks for all the ridiculously cheap shares at this point!

Good Update.....things are brewing .....Got right back to me

On 03/19/13, Mark Schena<mark@arrayit.com> wrote:

Hi Michael, The Affymax announcement probably improves our chances for a deal because it creates urgency for a companion diagnostic. PRs will be forthcoming shortly. Thanks, mark

Sent from my iPhone


Mark Schena, Ph.D.
President
Arrayit Corporation (ARYC)
524 East Weddell Drive
Sunnyvale, CA 94089
USA


Phone 408-744-1331
Fax 408-744-1711
Mobile 650-248-8710
Email mark@arrayit.com
Web http://arrayit.com


Notice of content filtering and monitoring: Arrayit Corporation and its subsidiaries and business units (collectively, “Arrayit” and “the Company”) reserve the right to monitor, filter and archive all e-mail communications sent and/or received by its employees. Arrayit is not responsible for any typographical error and any pricing or offers contained in this e-mail are subject to change without notice. Notice of proprietary and/or material information: This e-mail and any of its attachments may contain proprietary and/or material information that may be deemed privileged, confidential or subject to copyright belonging to Arrayit. This e-mail is intended solely for the use of the individual or entity to which it is addressed. If you are not the intended recipient of this e-mail, you are hereby notified that any dissemination, distribution, copying, or action taken in relation to the contents of and attachments to this e-mail is strictly prohibited and may be unlawful. If you have received this e-mail in error, please notify the Sender immediately by telephone at 408-744-1331, and permanently delete the original and any copy or printout. Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this email may include forward-looking statements that involve certain risks and uncertainties detailed in the Company’s filings with the Securities and Exchange Commission. For information provided by Arrayit with respect to its business and business prospects, as well as the risks associated with an investment in our Company’s publicly traded securities, please see the Company’s reports filed with the U.S. Securities and Exchange Commission, copies of which are available at www.sec.gov and also on the Company website, found at www.arrayit.com.

On Mar 19, 2013, at 5:29 AM, xxxx@verizon.net wrote:


Hello All
I am assuming with Affymax's announcement yesterday, does this put them out of the picture?

Also, can we get any PR updates on events happening, its been pretty quiet for a long time now?

Thanks again for your responses, really looking forward to seeing results after all these years now?

Yep Divy is going to be 1:3

So better than last time....

But with where that prices considering it will be on NASDAQ

Your talkin $2-$3 a share min.

I'll take it, thats why everyone should be loading up down here, that s a HUGE divy....

He Did, I dont think I can attach anything to my message though

I will copy and paste the words from the news letter, its professionally done..

Avant Diagnostics, Inc. is a life sciences company located in Scottsdale, AZ. Our mission is to Save Lives through Early Detection of Life Threatening Cancers via proprietary, protein based microarray diagnostic tests. The company’s first test, OvaDx, represents a breakthrough in early stage detection of Ovarian Cancer (OC). Currently available OC diagnostic tests have not secured the endorsement of independent medical organizations for routine screening due to poor specificity. To date, OvaDx has shown 100% specificity and a favorable IP position. The company’s diagnostic pipeline includes: Pancreatic Cancer, Parkinson ’s disease, Alzheimer’s Disease, and Breast Cancer.
Ovarian Cancer (OC) itself represents a material opportunity for the company. Sadly, OC is the 5th leading form of cancer death among women, and the routine screening of any risk group has not been endorsed by any of the leading independent medical organizations, including ACOG, ACS or USPSTF due to the potential harm caused by false positive tests. AVANT Diagnostics has completed initial testing (257 patients) of the company’s OC diagnostic test with impressive results – no false positives or 100% specificity and 79.7% sensitivity. The FDA requires AVANT complete a 500 patient retrospective study for the pre-IDE submission, followed by a 2,000 patient prospective study to secure product approval. Our strategy is to complete and publish the retrospective study, giving us statistical relevance, raise sufficient additional capital to complete the prospective testing and bring the product to market. We intend to repeat this process with the other diagnostics in our pipeline.
Additionally, the company enjoys a very favorable IP position. To date, Avant Diagnostics has filed two patents, one for a device and the other for a method. Avant Diagnostics also expects a favorable reimbursement position since OvaDx is a new device (vs. an ELISA), and includes more than 100 biomarkers. The company is currently seeking a capital investment in order to complete phase one of the FDA mandated trials, effectuate the publication and strategic partner strategy, complete the initial public offering and lay the foundation for a successful commercialization strategy.
Total $1,000,000
o Retrospective Analysis $500,000
o Operating Capital $350,000
o Public Offering $150,000
Steven Scott, CEO 617-448-1300 sscott@avantdiagnostics.com
Gregg Linn, COO/CFO 602-524-4165 glinn@avantdiagnostics.com
8561 E. Anderson Drive, Suite 104 Scottsdale, AZ 85255
Introduction
Opportunity
Required
Capital

More Info and due diligence....This could be your retirement party folks, give a little taste to your friends too!

On 03/14/13, Steven Scott<sscott@avantdiagnostics.com> wrote:

We are in the process of completing a one million dollar private placement, the purpose is to get the 500 retrospective tests done for submission to the FDA. This should take about sixty days from completion of funding, and publish the results. Assuming that we get results similar to the in house testing, the value of Avant Diagnostics should increase dramatically. At that point we would re-file the registration statement and become a public company. We hope to add an underwriter as well. Array is the entity that is going to dividend the stock, as such, it is in their hands to do so.



I have enclosed an executive summary. Feel free to contact me if you would like any information on the private placement.



Regards,



Steven Scott,CEO

Avant Diagnostics,Inc.

O 480-767-7733

C 617-448-1300

C 480-414-5566



From: xxxx@verizon.net [mailto:xxxx@verizon.net]
Sent: Thursday, March 14, 2013 10:37 AM
To: arrayit@arrayit.com; xxxx@verizon.net
Cc: sscott@issuerscap.com
Subject: Re: Re: Urgent Please Respond



Thats great, really appreciate the info



Steve

Can you give me an update on the timing of the dividend, when does the capital raise go into play

Also, when is the FDA approval going to be sent?



Thanks so much for your help and I look forward to adding to my very large position.





On 03/14/13, arrayit@arrayit.com wrote:



Dear Michael, Enclosed is Dr. Schena's response from yesterday. Thanks
very much for your support!


Arrayit Corp


From: mark@arrayit.com
Subject: Re: Urgent Please Respond
Date: March 13, 2013 11:34:10 AM PDT
To: xxxx@verizon.net
Cc: sscott@issuerscap.com

Hi Michael, Very nice to hear from you! Are you the PT in Buffalo or
another shareholder? Either way, we appreciate your support. Here's the
info. Thanks, mark



On Mar 13, 2013, at 9:45 AM, xxxx@verizon.net wrote:

Hello Arrayit Corp
I have been a long time very frustrated investor (own 151,000 shares) of
your company and I am looking for some answers to my questions below.

Rene and I own 22,000,000 shares of ARYC, so believe me when I tell you we
are on the same team!



Please be as specific as you can.

1. When is the spinoff going to be approved and happen so that we receive
our shares

Our new CEO Steve Scott of Avant Diagnostics plans to distribute the
dividend as soon as possible after the initial $1M capital raise. Steve
can provide an update.



2. What is going on with the financing for a possible FDA approval in 2Q

Steve can provide an update on the financing and FDA submission.



3. Is there a partnership on the horizon with AFFY - Affymax?

We have reached out to Affymax (AFFY) with a very exciting proposal and we
are awaiting a response from the company's Chief Medical Officer.




I anxiously look forward to your detailed response to these questions above

Thanks

Michael

Here is some of the info I get verbally and now in writing.

I have also reached out to Steve (below) on the specific dates

Big things just around the corner my friends...Very big things!!




On 03/14/13, arrayit@arrayit.com wrote:

Dear Michael, Enclosed is Dr. Schena's response from yesterday. Thanks
very much for your support!


Arrayit Corp


From: mark@arrayit.com
Subject: Re: Urgent Please Respond
Date: March 13, 2013 11:34:10 AM PDT
To: xxxx@verizon.net
Cc: sscott@issuerscap.com

Hi Michael, Very nice to hear from you! Are you the PT in Buffalo or
another shareholder? Either way, we appreciate your support. Here's the
info. Thanks, mark



On Mar 13, 2013, at 9:45 AM, xxxx@verizon.net wrote:

Hello Arrayit Corp
I have been a long time very frustrated investor (own 151,000 shares) of
your company and I am looking for some answers to my questions below.

Rene and I own 22,000,000 shares of ARYC, so believe me when I tell you we
are on the same team!



Please be as specific as you can.

1. When is the spinoff going to be approved and happen so that we receive
our shares

Our new CEO Steve Scott of Avant Diagnostics plans to distribute the
dividend as soon as possible after the initial $1M capital raise. Steve
can provide an update.



2. What is going on with the financing for a possible FDA approval in 2Q

Steve can provide an update on the financing and FDA submission.



3. Is there a partnership on the horizon with AFFY - Affymax?

We have reached out to Affymax (AFFY) with a very exciting proposal and we
are awaiting a response from the company's Chief Medical Officer.




I anxiously look forward to your detailed response to these questions above

Thanks

Michael



On Thu, March 14, 2013 7:59 am, xxxx@verizon.net wrote:
>

>
>
>
>
>
>
> Hello Arrayit Corp
>
>
> I have been a long time very frustrated investor (own 151,000 shares) of
> your company and I am looking for some answers to my questions below.
>
>
> Please be as specific as you can.
>
>
>
>
> 1. When is the spinoff going to be approved and happen so that we receive
> our shares
>
> 2. What is going on with the financing for a possible FDA approval in 2Q
>
>
> 3. Is there a partnership on the horizon with AFFY - Affymax?
>
>
>
>
> I anxiously look forward to your detailed response to these questions
> above
>
>
>
> Thanks
>
>
>
>
> Michael >
>
>
>
>
>
>
>
>

Couldnt agree more, they gave good info when you call them

I think the upside with everthing that is going on with this company is a real game changer

Thinking about snatching that 20K at .185

I want this to be the biggest gain ever in 18 years....

i do not get into the "science" of things ....I do extensive research by making calls getting reports and i
n this case having a friend verify address and business is completely legit . All that said i have over 25k in this from my diligence...never made that big of an investment in one stock like this i did the same with Xxii from .20 to 1.01 gnin from .59 to 2 bux and i am just as confident here.....

I hear ya brother, but you should revisit that convo,

You will be excited to hear what a difference a year has made...

I am with you that nothing is a guarantee,

But so many factors are in play and specifics on timeframes were given

I havent wet myself yet, but have the rubber sheets ready lol....

GLTA!

No doubt, but I havent invested this much into a company such as this in a long time

Did a lot of due diligence on this one. Feel bad its taken so long for all those that have been waiting since 2010, but this is finally coming to fruition...

Shorts are gonna feel some pain on this one.

Nothing is a guarantee in life, but confidence is very high with this one.

GLTA

Well, what I really can say is..

You have 3 weeks or less to load up on cheap shares according to their timeframe they disclosed when you give them a call.

I wouldnt be investing $25,000 without doing my due diligence, thats all I am saying my friends....

22000 More For Me, thanks for the Ridiculously Cheap Shares!

Thats 150K in the bank, this is a retirement stock right here

Called the company again today, re-affirmed everything I had asked a couple weeks ago.

You will all see very soon what I am talking about

$1, $2....

And the spinoff, which is almost finished.

And the more exposure and media.

Enjoy the ride up....

That a Great GREAT Find Dr!

This thing will run to $1, $2, who knows when you have that small of a float and market cap and you have the tecnologies, spinoff, etc all coming to head at one time.

I am buying more tomorrow

128K and counting

Lets see some other buyers get this attention, get it running and then you will see the volume spike!

Lots of BIG BULK BUYS...Insiders loading up again

Big News is coming, we were told about it, and now we seeing the volume in advance of it,

Cannot wait for this thing to really take off to the $2-$3 range by summer....

All the patents, and everything else the company has going for it will make 2013 a dream year for this company!

Cheap Shares under .20 still available

This stock has unbelievable potential returns, $1, $2 is very realistic and with a spinoff pending and revenues alredy being obtained, having shares available down here is unbelievable

I have 128,000, no lie, and this is going to be my kids college fund if not a retirement party in the months and years to come!!

Grab em while you can and good luck to all longs, you will enjoy this ride up.

This is your low, new highs will be in the 1.50 range

Could not agree more, fresh buyers, huge volume for this stock yesterday, and a large number of big blocks filled by shorts who will be squeezed in a big way

$1.50 by June.....

Big BIG News Coming

Call the company, they will give you the same insight.

Enjoy the ride up!

LOTS of huge Bids filled today

25K blocks at least 4 of them

Do you think a mutual fund is buying?

Do you think someone know something

I most certainly think so

See everyone at $3 or higher

Contact the CO. they will tell you

Accumulation Happening, Financing almost complete

Big Things about to happen, stock poised to take off to new highs.

Do your research and you will see.

Perfect situation here....

GLTA

MUST SEE DIVIDEND ANNOUNCED - TRLI

Company announces a 1 for 5 Forward dividend

Extremely Low Market Cap
Positive Revenues
A steal down at these prices

http://finance.yahoo.com/news/truli-media-group-inc-announces-133000834.html

This could easily hit .40-.50 with no problem from here,

Get in early..

GLTA!